У вашего броузера проблема в совместимости с HTML5
The big "late-breaking" news at the American Society of Hematology Annual Meeting are the results of the phase 3 CANDOR trial. Dr Katja Weisel, University Medical Center Hamburg-Eppendorf in Germany, explains for Myeloma Patients Europe (MPE) in this video the main results of this clinical trial.